The time-honored approach of quantifying agonist selectivity through measurement of agonist affinity with binding and efficacy through potency ratios in model assays for prediction of effect in therapeutic systems can fall short of providing useful answers for functionally selective agonists. Agonists are now known to have pluridimensional efficacies that are associated with selected signalling pathways coupled to the receptor. This necessitates specifically tailored assay formats to measure predetermined efficacies of ligands to characterize agonist selectivity fully. If such assays can access signalling that directly emanates from the interaction of the agonist-bound receptor and a cytosolic signalling protein, then the Black/Leff operational model can be used to specifically quantify 'transduction ratios' (t/KA) that fully characterize selective activation of signalling pathways by a given agonist. As whole-cell processing of pleiotropic signalling cascades imposes cell-specific phenotypic agonist profiles, ultimately the assessment of agonist selectivity is most reliably done in the therapeutically relevant primary cell system. (2010) The paper in this issue of the BJP by Jillian Baker (Baker, 2010) emphasizes the importance of determining both the affinity and efficacy of selective agonists in assessing overall selectivity of agonism. The value of this approach in determining agonist receptor selectivity is clear, as agonist potency can be controlled by affinity or efficacy, or both. This basic pharmacological principle can be extended in light of our present knowledge of pleiotropic signalling through seven transmembrane receptors (7TMRs). Specifically, it is apparent that agonists activating receptors coupled to multiple signalling proteins can produce biased activation of some signalling pathways over others (see Kenakin, 2006;Mailman, 2007). Under these circumstances, conventional whole-cell measures of affinity (binding) and efficacy (whole-cell potency ratios) can be misleading. It is therefore worth discussing the concept of agonist selectivity in the functionally selective world. 7TMRs are allosteric systems mediating the vectorial transduction of energy from one locus on the receptor to another. Figure 1 Classical allosteric system for 7TMR agonism. All agonists become the 'modulator', the receptor is the 'conduit' and the cytosolic signalling molecules are the 'guests'. Within this scheme, the Black/Leff operational model can be used to quantify selective activation of pathways through identification of unique log(t/KA) ratios.
British Journal of Pharmacology